Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

First US Case Of Antibiotic Resistance To Last Resort Drug Signals Need For New Treatments

XTALKS VITALS NEWS

Antibiotic Resistance

While the 49-year-old woman has been successfully treated with another antibiotic, researchers are concerned that this resistance could be passed to other bacteria, potentially leading to an outbreak of antibiotic-resistant superbugs.

Share this!

May 30, 2016 | by Sarah Massey, M.Sc.

According to a report issued on Thursday, the first patient to develop a bacterial infection that carries resistance to an antibiotic used to treat tough infections, has been identified in the US. While the 49-year-old woman has been successfully treated with another antibiotic, researchers are concerned that this resistance could be passed to other bacteria, potentially leading to an outbreak of antibiotic-resistant superbugs.

“It is the end of the road for antibiotics unless we act urgently,” said Dr. Tom Frieden, director of the Centers for Disease Control and Prevention (CDC). Other countries – including China – have encountered multi-drug resistant pathogens, for which no known antibiotic treatments exist.

The Pennsylvania-based woman was diagnosed with a urinary tract infection in April, and was prescribed a course of antibiotics. Diagnostic tests showed that the woman was infected with a strain of E. coli, a common type of gut bacteria that can migrate to the bladder.

Further tests however, revealed that this strain of bacteria was resistant to most antibiotics used as first-line therapies for this type of infection. Even more alarming was the discovery that the bacteria possessed antibiotic resistance genes for the drug, colistin.



Colistin is a relatively old antibiotic, and most doctors stopped using the by the 1970s due to its unpleasant side effects. It has proven to be effective in recent years however, against bacteria that are resistant to most other over-used antibiotics.

When patients present with infections that are resistant to carbapenems – a class of antibiotics used after other treatments have failed – doctors prescribe colistin. If other pathogens acquire the colistin-resistance genes seen in the Pennsylvania woman, many people could be at risk of developing completely antibiotic-resistant infections.

“This is another piece of a really nasty puzzle that we didn't want to see here,” said Dr. Beth Bell, who oversees CDC's emerging infectious diseases programs. According to officials, the woman with the antibiotic resistant infection had not travelled outside the US in recent months. The CDC is now working to identify how and where the woman may have become infected.


Keywords: Antibiotic Resistance, Bacterial Infection, CDC


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA

March 27, 2017 - Pfizer and Merck KGaA’s PD-L1 inhibitor, Bavencio (avelumab), has become the first immunotherapy to be approved by the US Food and Drug Administration (FDA) to treat a rare form of skin cancer, known as metastatic Merkel cell carcinoma (MCC).

Featured In: Biotech News


New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.